Badalona Applied Research group in Oncology (B·ARGO)
Ricard Mesía Nin
Anna Martínez Cardús
The Group Badalona Applied Research group in Oncology (B·ARGO) is a new transversal organization of the translational and clinical research that has been carried out for many years at the IGTP, the Germans Trias University Hospital (HUGTiP) and the Catalan Institute of Oncology (ICO) Badalona at the HUGTiP. The group consists of senior researchers, junior researchers and fellows from the IGTP and personnel of the Medical Oncology Department of the ICO who are affiliated to the IGTP.
The multidisciplinary group is made up of over 30 professionals working on the different aspects of research.
The mission of the B·ARGO is to be a translational research group of excellence that contributes to the application of personlized oncology.
The vision of the B·ARGO is to maintain an integrated cancer research and healthcare system that optimizes the management of cancer patients and improves the length and quality of their lives.
The general aims of the B·ARGO are:
- To fill the existing gap between clinical and basic research
- To identify new strategies, emerging from basic research and apply them in clinical practice
- To typify new biomarkers for cancer diagnosis and prognosis
- To identify new predictive biomarkers of response to current anti-neoplasic therapies
- To determine biomarkers for tumor resistance acquisition during exposure to treatment
To carry out these aims B·ARGO research is organized three areas:
Anna Martínez Cardús(ELIMINAR), PhD Transversal Scientific Coordinator
Thoracic tumors, Sarcoma, Central Nervous System and Radiotherapy
Members of the team
Central Nervous System
Carme Balañá, MD PhD(ELIMINAR)
Anna Estival, MD PhD(ELIMINAR)
Marta Domenech, MD
Breast , Gynaecological, and Head and Neck Tumors
Margarita Romeo, MD PhD(ELIMINAR)
Digestive, Urological and Skin tumors and Carcinoma of unknown primary
Carcinoma of unknown primary (CUP)
Olatz Etxaniz, MD PhD(ELIMINAR)
Validación y desarrollo de un biomarcador efectivo a la respuesta terapéutica frente a antimetabolitos usados para el tratamiento de cáncer
Principlal Investigator: Ester Ballana and Mireia Margelí
Start Date: 01/01/2018
End Date: 31/12/2020
Caracterización molecular integral del glioblastoma correlación clinico-radiologica, genomica, transcriptómica e inmunohistoquimica
Principlal Investigator: Carme Balañá
Start Date: 01/01/2019
End Date: 31/12/2022
Cáncer de veixiga invasivo: hacia una medicina de precisión
Principlal Investigator: Albert Font
Start Date: 01/01/2015
End Date: 31/12/2021
A study of patients with ovarian cancer highlights the need to identify the mechanisms of resistance to PARP inhibitors to find effective therapies for this tumour
Retreatment with platinum-based chemotherapy as a therapy for relapsed ovarian cancer after progression to PARP inhibitors shows different results for patients with BRCA-mutated and BRCA wild-type tumours.
CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.